- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05990530
Allogeneic Transplantation of Expanded Pancreatic Islet Cells
August 7, 2023 updated by: Shanghai Jiao Tong University School of Medicine
Evaluation of the Efficacy and Safety of Allogeneic Transplantation of Expanded Pancreatic Islet Cells in Patients With "Brittle" Type 1 Diabetes
This study will evaluate the efficacy and safety of allogeneic pancreatic islet cells transplantation in patients with "brittle" type 1 diabetes.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
6
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Weiqiong Gu, PhD
- Phone Number: 671701 86-21-64370045
- Email: Gwq10978@rjh.com.cn
Study Locations
-
-
-
Shanghai, China, 200025
- Recruiting
- Department of Endocrinology and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao-Tong University
-
Contact:
- Weiqiong Gu, PhD
- Phone Number: 672701 86-21-64370045
- Email: Gwq10978@rjh.com.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Voluntarily sign an informed consent form and agree to comply with the trial treatment plan and visit schedule.
- Age ≥18 years and ≤60 years on the day of signing the informed consent form, regardless of gender.
- Body mass index (BMI) ≥18.0 kg/m2 and ≤35.0 kg/m2.
- Diagnosed with T1DM based on the World Health Organization's diabetes classification (2019).
- HbA1c ≥7.0% and ≤15.0% at screening.
- Dependence on insulin injection therapy for ≥5 years, receiving a stable insulin treatment plan for ≥3 months, and injecting insulin three or more times per day or using an insulin pump.
- Postprandial mixed meal stimulated C-peptide level <0.3 ng/mL.
- Experienced impaired awareness of hypoglycemia or significant glycemic instability during screening and in the past 6 months. Hypoglycemic episodes are associated with impaired awareness of hypoglycemia, extreme glycemic instability, or severe fear and maladaptive behavior.
- Sexually active males who are not surgically sterilized or have partners of childbearing potential agree to use effective contraception during the entire trial period and for at least 6 months after the study ends; sexually active females of childbearing potential agree to use effective contraception during the entire study period and for at least 6 months after the study ends.
Exclusion Criteria:
- Types of diabetes other than T1DM.
- Body mass index (BMI) >35 kg/m2 or weight <50 kg.
- Excessive insulin sensitivity and/or insulin resistance (insulin requirement >1.0 IU/kg/day or <15 U/day).
- Previous pancreatic or islet transplantation. Severe trauma, severe infection, or surgery that may affect glycemic control within one month before screening.
- History of hypertension with systolic blood pressure (SBP) >160 mmHg and/or diastolic blood pressure (DBP) >100 mmHg after stable dose (at least 4 weeks) of antihypertensive medication.
- Blood transfusion or severe bleeding within the past 3 months, known hemoglobin-related diseases, anemia (moderate to severe), or other known hemoglobinopathies that interfere with HbA1c measurement (such as sickle cell disease).
- Impaired liver or kidney function at screening: aspartate aminotransferase (AST) ≥3 times the upper limit of normal (ULN), alanine aminotransferase (ALT) ≥3 times ULN, total bilirubin level (TBL) ≥2 times ULN (excluding Gilbert's syndrome), creatinine clearance rate <45 mL/min (calculated by the Cockcroft-Gault formula).
- Significant albuminuria (urinary albumin excretion rate >300 mg/g) or history thereof.
- Uncontrolled or untreated thyroid disease or adrenal insufficiency.
- Severe diabetic kidney disease or renal insufficiency, proliferative retinopathy, diabetic foot ulcers, diabetes-related amputation, and/or severe peripheral neuropathy at screening.
- Active hepatitis B, hepatitis C, acquired immunodeficiency syndrome, syphilis, or tuberculosis. Even without clinical evidence of active infection, participants with laboratory evidence of active infection are also excluded.
- Severe heart disease or a history of cardiovascular disease within 6 months before screening, including stroke, decompensated heart failure (NYHA class III or IV), myocardial infarction, unstable angina, or coronary artery bypass grafting.
- Previous history of coagulation disorders or requiring long-term anticoagulant therapy (e.g., warfarin) (low-dose aspirin therapy is allowed) or patients with INR >1.5.
- Substance abusers with a history of drug abuse/dependence or drug use within 1 year before screening.
- Received live vaccines within 14 days before screening or planned to receive live vaccines during the trial or within 1 month after treatment. Live vaccines include, but are not limited to, measles, mumps, rubella, varicella, yellow fever, rabies, Bacillus Calmette-Guérin, typhoid vaccine, COVID-19 vaccine, etc.
- Patients with a history of acute or chronic pancreatitis, symptomatic gallbladder disease, pancreatic injury, or other high-risk factors for pancreatitis, or patients with blood amylase >1.2 times ULN at screening.
- Other abnormal laboratory test results deemed clinically significant by the investigator.
- Patients with severe mental illness.
- Participated in a drug or medical device clinical trial within the past 3 months and received investigational drugs or medical devices; or within 5 half-lives of another drug before screening (if the half-life exceeds 3 months).
- Currently receiving long-term (continuous for ≥14 days) systemic pharmacological doses of glucocorticoids or other medications that may affect the participant's consciousness.
- Treatment (local, intra-articular, intraocular, or inhalation preparations) for any other factors or diseases not mentioned above, deemed unsuitable for participation in this clinical study by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: YD02-2022
|
Human islet cells were isolated and expanded in vitro to generate islets containing all types of pancreatic endocrine cells and possessing comparable function of human islets.
These islet cells will be infused into the hepatic portal vein.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Residual β-Cell function (RBCF)
Time Frame: 12 months post-transplant
|
Evaluation of the magnitude of C-peptide change after transplantation
|
12 months post-transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glycemic control (MAGE)
Time Frame: 12 weeks and 52 weeks post-transplant
|
Evaluation of the average amplitude of glycemic fluctuations (MAGE) in subjects
|
12 weeks and 52 weeks post-transplant
|
Quality of life score
Time Frame: baseline and 52 weeks post-transplant
|
Evaluation of the quality of life score in subjects
|
baseline and 52 weeks post-transplant
|
Glycemic control (HbA1c)
Time Frame: 52 weeks post-transplant
|
Evaluation of the proportion of subjects with HbA1c ≤7.0% and no severe hypoglycemic events
|
52 weeks post-transplant
|
Treatment (insulin-independent)
Time Frame: 12 weeks and 52 weeks post-transplant
|
Evaluation of the proportion of subjects who are insulin-independent
|
12 weeks and 52 weeks post-transplant
|
Treatment (insulin requirement)
Time Frame: 12 weeks and 52 weeks post-transplant
|
Evaluation of the percentage reduction in insulin requirement
|
12 weeks and 52 weeks post-transplant
|
Hypoglycemia (HYPO)
Time Frame: baseline and 52 weeks post-transplant
|
Evaluation of the severity of hypoglycemia using the Ryan Hypoglycemia Severity Score (HYPO)
|
baseline and 52 weeks post-transplant
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 22, 2023
Primary Completion (Estimated)
August 1, 2024
Study Completion (Estimated)
August 1, 2025
Study Registration Dates
First Submitted
August 7, 2023
First Submitted That Met QC Criteria
August 7, 2023
First Posted (Actual)
August 14, 2023
Study Record Updates
Last Update Posted (Actual)
August 14, 2023
Last Update Submitted That Met QC Criteria
August 7, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- YD02-2022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brittle Type 1 Diabetes
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Hadassah Medical OrganizationOramed Pharmaceutical Inc.CompletedBrittle Type I Diabetes MellitusIsrael
-
Centre d'Etudes et de Recherche pour l'Intensification...CompletedDiabetes Mellitus, Type 1 | Diabetes Mellitus, Brittle | Closed-LoopFrance
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
Clinical Trials on YD02-2022
-
Shanghai Jiao Tong University School of MedicineRecruitingDiabetes After Total PancreatectomyChina
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruitingAdvanced Malignant Cancer
-
University of CalgaryAlberta Innovates Health Solutions; Wave View ImagingNot yet recruitingHealthy | Breast
-
University Hospital, CaenCompletedHeart Failure | Cancer, Therapy-RelatedFrance
-
Xijing HospitalRecruitingCOVID-19 | Postoperative Complications | SurgeryChina
-
Cairo UniversityRecruiting
-
Sanofi Pasteur, a Sanofi CompanyCompletedHealthy Volunteers | Influenza ImmunizationUnited States
-
Radboud University Medical CenterGlaxoSmithKlineCompletedInfluenza | Herpes ZosterNetherlands
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza ImmunizationUnited States, Denmark, Poland, Spain, Czechia
-
Centrexion TherapeuticsTerminatedAcute-onset Herpes Zoster PainAustralia